Tempus AI (TEM) Soars 15% on $1.1-Billion Deal

Group 1 - Tempus AI Inc. (NASDAQ:TEM) experienced a significant stock increase of 15% to $76.33, driven by strong demand for its services and $1.1 billion in sealed contracts, with a revenue retention rate of approximately 126% last year [1][4] - The company secured data agreements with 70 customers in the past year, including major pharmaceutical firms such as AstraZeneca, GlaxoSmithKline, and Pfizer, as well as various biotechnology companies [2] - The Chief Finance Officer of Tempus AI highlighted that 2025 was a record year for the company's Data and applications business in terms of revenue and total contract value (TCV) [3] Group 2 - The company expressed confidence in its growth trajectory, stating that its engagement with life sciences companies has strengthened, positioning its data business for continued growth into 2026 and beyond [4] - Tempus AI plans to announce its finalized financial and operating performance for 2025 during an earnings call scheduled for February 2026 [4]